Logotype for Passage Bio Inc

Passage Bio (PASG) investor relations material

Passage Bio H.C. Wainwright 27th Annual Global Investment Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Passage Bio Inc
H.C. Wainwright 27th Annual Global Investment Conference summary5 Sep, 2025

Key program highlights

  • Lead program PBFT02 targets frontotemporal dementia (FTD) with GRN and C9orf72 mutations, affecting about 39,000 patients in the US and Europe.

  • PBFT02 uses AAV1 capsid for gene therapy, administered via intracisterna magna for broad CNS distribution and lower dosing.

  • Phase 1/2 trial is open-label, multicenter, with sites in the US, Canada, Portugal, and Brazil; three dosing cohorts planned.

  • Key biomarkers include CSF progranulin and plasma neurofilament levels, with clinical response measured by a modified dementia rating scale.

  • Upcoming milestones: regulatory feedback on manufacturing in H2 2025, interim data and registrational trial design in H1 2026.

Clinical data and safety

  • Dose one showed robust, durable increases in CSF progranulin, exceeding healthy adult levels at 12 and 18 months.

  • Dose two, at half the level, also reached normal progranulin range at 30 days; all future patients to receive this dose.

  • Plasma neurofilament levels, a marker of neurodegeneration, increased only 3.7% per year in treated patients vs. 29% in untreated.

  • Three of eight patients experienced venous thromboembolic events; protocol now includes prophylactic anticoagulation with low-dose apixaban.

  • No clinically significant immune responses or complications from the administration procedure observed.

Competitive positioning and future plans

  • PBFT02 achieves higher and more durable progranulin levels than other therapies, including monthly IV antisortillin antibody and another AAV9 gene therapy.

  • One-time administration is expected to be preferred by patients and families over chronic therapies.

  • Protocol updates will include earlier-stage patients and exclude more severe cases.

  • Expansion to FTD C9 patients planned for later this year; preclinical Huntington’s disease program advancing.

  • Cash balance of $58 million provides runway into Q1 2027.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Passage Bio earnings date

Logotype for Passage Bio Inc
Chardan’s 9th Annual Genetic Medicines Conference21 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Passage Bio earnings date

Logotype for Passage Bio Inc
Chardan’s 9th Annual Genetic Medicines Conference21 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company utilizes a proprietary gene therapy platform in collaboration with the University of Pennsylvania’s Gene Therapy Program to deliver adeno-associated virus (AAV)-based therapeutics directly to the CNS. Passage Bio’s pipeline includes treatments targeting conditions such as frontotemporal dementia, Krabbe disease, and other inherited neurodegenerative and neurodevelopmental disorders. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage